https://orcid.org/0000-0002-6593-0140
Key Points
hCKTs (≥5 CAs) and translocations are independent prognostic factors for inferior PFS in patients with TP53-intact CLL treated with venetoclax-based combinations.
Although CIT was associated with an increase in CAs at clinical progression of CLL, karyotype complexity did not increase after venetoclax-based treatments.
Abstract
Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy (CIT), whereas their prognostic impact in the context of venetoclax-based treatments is still debated. In this prospective analysis on karyotype complexity in CLL, we evaluated the impact of complex (≥3 chromosomal aberrations [CAs], CKTs) and highly complex karyotypes (≥5 CAs; hCKTs) as well as specific aberrations in previously untreated patients without TP53 aberrations undergoing either CIT or time-limited venetoclax-based therapies in the phase 3 GAIA/CLL13 trial. Karyotype analyses were available for 895 of 926 patients (96.7%), of whom 153 (17%) had a CKT and 43 (5%) hCKT. In the CIT arm, CKT was associated with shorter progression-free survival (PFS) (hazard ratio [HR] 2.58; 95% confidence interval [95% CI], 1.54-4.32; P < .001) and overall survival (HR, 3.25; 95% CI, 1.03-10.26; P = .044). In the pooled venetoclax arms, a multivariable analysis identified hCKTs (HR, 1.96; 95% CI, 1.03-3.72; P = .041), but not CKTs, as independent adverse prognosticators for PFS. The presence of translocations (unbalanced and/or balanced) was also independently associated with shorter PFSs in the venetoclax arms. CIT led to the acquisition of additional CAs (mean CAs, 2.0-3.4; from baseline to CLL progression), whereas karyotype complexity remained stable after venetoclax-based treatments (2.0, both time points). This analysis establishes highly complex karyotypes and translocations as adverse prognostic factors in the context of venetoclax-based combination treatments. The findings of this study support the incorporation of karyotyping into the standard diagnostic workup of CLL, because it identifies patients at high risk of poor treatment outcomes and thereby improves prognostication. This trial was registered at www.clinicaltrials.gov as #NCT02950051.
References
1.
Fischer
K
, Al-Sawaf
O
, Bahlo
J
, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
. N Engl J Med
. 2019
;380
(23
):2225
-2236
.2.
Hallek
M
, Cheson
BD
, Catovsky
D
, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
. Blood
. 2018
;131
(25
):2745
-2760
.3.
Hallek
M
, Shanafelt
TD
, Eichhorst
B
. Chronic lymphocytic leukaemia
. Lancet
. 2018
;391
(10129
):1524
-1537
.4.
Stilgenbauer
S
, Eichhorst
B
, Schetelig
J
, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
. Lancet Oncol
. 2016
;17
(6
):768
-778
.5.
Stilgenbauer
S
, Eichhorst
B
, Schetelig
J
, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial
. J Clin Oncol
. 2018
;36
(19
):1973
-1980
.6.
Byrd
JC
, Harrington
B
, O'Brien
S
, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia
. N Engl J Med
. 2016
;374
(4
):323
-332
.7.
Munir
T
, Brown
JR
, O'Brien
S
, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
. Am J Hematol
. 2019
;94
(12
):1353
-1363
.8.
O'Brien
S
, Furman
RR
, Coutre
S
, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
. Blood
. 2018
;131
(17
):1910
-1919
.9.
Sharman
JP
, Egyed
M
, Jurczak
W
, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
. Lancet
. 2020
;395
(10232
):1278
-1291
.10.
Woyach
JA
, Ruppert
AS
, Guinn
D
, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia
. J Clin Oncol
. 2017
;35
(13
):1437
-1443
.11.
Woyach
JA
, Ruppert
AS
, Heerema
NA
, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
. N Engl J Med
. 2018
;379
(26
):2517
-2528
.12.
Kater
AP
, Owen
C
, Moreno
C
, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities
. NEJM Evid
. 2022
;1
(7
):EVIDoa2200006
.13.
Jain
N
, Keating
M
, Thompson
P
, et al. Ibrutinib and venetoclax for first-line treatment of CLL
. N Engl J Med
. 2019
;380
(22
):2095
-2103
.14.
Burger
JA
, Tedeschi
A
, Barr
PM
, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
. N Engl J Med
. 2015
;373
(25
):2425
-2437
.15.
Tausch
E
, Schneider
C
, Robrecht
S
, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
. Blood
. 2020
;135
(26
):2402
-2412
.16.
Zenz
T
, Eichhorst
B
, Busch
R
, et al. TP53 mutation and survival in chronic lymphocytic leukemia
. J Clin Oncol
. 2010
;28
(29
):4473
-4479
.17.
Döhner
H
, Stilgenbauer
S
, Benner
A
, et al. Genomic aberrations and survival in chronic lymphocytic leukemia
. N Engl J Med
. 2000
;343
(26
):1910
-1916
.18.
Baliakas
P
, Iskas
M
, Gardiner
A
, et al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data
. Am J Hematol
. 2014
;89
(3
):249
-255
.19.
Baliakas
P
, Jeromin
S
, Iskas
M
, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact
. Blood
. 2019
;133
(11
):1205
-1216
.20.
Herling
CD
, Klaumünzer
M
, Rocha
CK
, et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
. Blood
. 2016
;128
(3
):395
-404
.21.
Kreuzer
KA
, Furman
RR
, Stilgenbauer
S
, et al. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
. Leukemia
. 2020
;34
(1
):296
-300
.22.
Kruzova
L
, Schneiderova
P
, Holzerova
M
, et al. Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: a single center experience over 12 years
. Leuk Res
. 2019
;85
:106218
.23.
Puiggros
A
, Collado
R
, Calasanz
MJ
, et al. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
. Oncotarget
. 2017
;8
(33
):54297
-54303
.24.
Rigolin
GM
, Cavallari
M
, Quaglia
FM
, et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI
. Blood
. 2017
;129
(26
):3495
-3498
.25.
Rigolin
GM
, del Giudice
I
, Formigaro
L
, et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: clinical and biologic correlations
. Genes Chromosomes Cancer
. 2015
;54
(12
):818
-826
.26.
Rigolin
GM
, Saccenti
E
, Guardalben
E
, et al. In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics
. Br J Haematol
. 2018
;181
(2
):229
-233
.27.
Van Den Neste
E
, Robin
V
, Francart
J
, et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine
. Leukemia
. 2007
;21
(8
):1715
-1722
.28.
Juliusson
G
, Oscier
DG
, Fitchett
M
, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities
. N Engl J Med
. 1990
;323
(11
):720
-724
.29.
Heerema
NA
, Muthusamy
N
, Zhao
Q
, et al. Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
. Haematologica
. 2021
;106
(6
):1608
-1615
.30.
Mayr
C
, Speicher
MR
, Kofler
DM
, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia
. Blood
. 2006
;107
(2
):742
-751
.31.
Ahn
IE
, Tian
X
, Ipe
D
, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model
. J Clin Oncol
. 2021
;39
(6
):576
-585
.32.
Rigolin
GM
, Del Giudice
I
, Bardi
A
, et al. Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study
. Blood
. 2021
;138
(25
):2727
-2730
.33.
Strati
P
, Wang
F
, Tambaro
FP
, et al. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype
. Br J Haematol
. 2019
;187
(1
):e1
-e4
.34.
Al-Sawaf
O
, Lilienweiss
E
, Bahlo
J
, et al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
. Blood
. 2020
;135
(11
):866
-870
.35.
Kater
AP
, Levin
M-D
, Dubois
J
, et al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
. Lancet Oncol
. 2022
;23
(6
):818
-828
.36.
Kater
AP
, Wu
JQ
, Kipps
T
, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study
. J Clin Oncol
. 2020
;38
(34
):4042
-4054
.37.
Kittai
AS
, Miller
C
, Goldstein
D
, et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib
. Blood
. 2021
;138
(23
):2372
-2382
.38.
Mato
AR
, Thompson
M
, Allan
JN
, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
. Haematologica
. 2018
;103
(9
):1511
-1517
.39.
Thompson
PA
, O'Brien
SM
, Wierda
WG
, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens
. Cancer
. 2015
;121
(20
):3612
-3621
.40.
Eichhorst
B
, Niemann
CU
, Kater
AP
, et al. First-line venetoclax combinations in chronic lymphocytic leukemia
. N Engl J Med
. 2023
;388
(19
):1739
-1754
.41.
Anderson
MA
, Tam
C
, Lew
TE
, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
. Blood
. 2017
;129
(25
):3362
-3370
.42.
Leeksma
AC
, Baliakas
P
, Moysiadis
T
, et al. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study
. Haematologica
. 2021
;106
(1
):87
-97
.43.
Mato
AR
, Hill
BT
, Lamanna
N
, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
. Ann Oncol
. 2017
;28
(5
):1050
-1056
.44.
Visentin
A
, Bonaldi
L
, Rigolin
GM
, et al. The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia
. Br J Cancer
. 2019
;121
(2
):150
-156
.45.
Ramos-Campoy
S
, Puiggros
A
, Beà
S
, et al. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients
. Haematologica
. 2022
;107
(3
):593
-603
.46.
Davids
MS
, Roberts
AW
, Kenkre
VP
, et al. Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase I, First-in-Human Study
. Clin Cancer Res
. 2021
;27
(17
):4690
-4695
.47.
Zinzani
PL
, Flinn
IW
, Yuen
SLS
, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma
. Blood
. 2020
;136
(23
):2628
-2637
.48.
Baliakas
P
, Puiggros
A
, Xochelli
A
, et al. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference
. Haematologica
. 2016
;101
(7
):e299
-302
.49.
Ibbotson
R
, Athanasiadou
A
, Sutton
LA
, et al. Coexistence of trisomies of chromosomes 12 and 19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG-positive variant
. Leukemia
. 2012
;26
(1
):170
-172
.50.
Baliakas
P
, Espinet
B
, Mellink
C
, et al. Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations
. Hemasphere
. 2022
;6
(4
):e707
.51.
Eichhorst
B
, Robak
T
, Montserrat
E
, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
. Ann Oncol
. 2021
;32
(1
):23
-33
.© 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal